

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Yuji Yamamoto et al.

Application No.: 10/797,903

Confirmation No.: 3373

Filed: March 10, 2004

Art Unit: 1614

For: C-KIT KINASE INHIBITOR

Examiner: Anna Pagonakis

**VIA EFS WEB FILING – WWW.USPTO.GOV**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the “References Cited” on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material

information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

This supplemental Information Disclosure Statement is being filed *inter alia* to provide the Examiner with English counterparts of previously cited non-English patent documents as follows:

EP 1566379 for WO 04/039782;  
US 7,253,286 for WO 02/32872;  
US 7,005,430 for WO 01/47931;  
US 7,135,466 for WO 01/47890;  
US 6,797,823 and US 7,169,789 for WO 00/43366; and  
US 6,143,764 for WO 97/17329.

A credit card form to cover the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-1721, under Order No. 2003946-0080.

Dated: April 4, 2008

Respectfully submitted,

/Charles E. Lyon/  
Charles E. Lyon, D. Phil.  
Registration No.: 56,630  
CHOATE, HALL & STEWART  
2 International Place  
Boston, Massachusetts 02110  
(617) 248-5000  
Attorney for Applicant